AbbVie Stock Edges Higher on Positive Lymphoma Trial Data
AbbVie (ABBV) shares saw a slight increase of approximately 0.3% on October 6th following positive results from a clinical trial for its blood-cancer treatment, epcoritamab. The trial indicated that epcoritamab combined with R-CHOP reduced the risk of disease progression or death by 51% compared to a control group.